Clinical management of HIV/AIDS in children;Barn og HIV/AIDS -forebygging, oppfølging og behandling

Tidsskrift for den Norske Laegeforening

Volumn 120, Issue 2, 2000, Pages 210-214

  Wathne, Karl Olaf ^a   Andersen, Guro L ^a  

^a Seksjon for Infeksjonssykdommer   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHILD; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; NEWBORN; NORWAY; PREGNANCY; PREGNANCY COMPLICATION; PRESCHOOL CHILD; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INFANT; INFANT, NEWBORN; NORWAY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 0034688067     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morbid Mortal Wkly Rep 1998; 47 (RR - 4): 1-43.
2. Centers for Disease Control and Prevention. Public Health Service Task Force Recommendations for the use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR Morbid Mortal Wkly Rep 1998; 47 (RR - 2): 1-29.
3. Recommendations for the management of HIV-infected women and their infants - a European consensus. Prenat Neonat Med 1999; 4: 3-17.
4. UNAIDS. Report on the Global HIV/AIDS Epidemic, December, 1998. Genève: UNAIDS, 1998.
5. AIDS og HIV-infeksjon meldt til Folkehelsa. MSIS-rapport 1999; 27: 14.
6. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double blind controlled trial of immediate and deferred zidovudine in asymptomatic HIV infection. Lancet 1994; 343: 871-81.
7. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91.
8. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339: 1261-8.
9. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA 1998; 279: 930-7.
10. Pediatric European Network for Treatment of AIDS. PENTA News 1999; 2: 4.
11. Mueller BU, Nelson RP, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM et al. A phase I/II study of the protease inhibitor retonavir in children with human immunodeficiency virus infection. Pediatrics 1998; 101: 335-43.
12. Hannet I, Erkeller-Yuksel F, Lydyard P, Deneys V, DeBruyere M. Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today 1992; 13: 215-8.
13. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA et al. Disease progression in HIV - infected infants and children: predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. JAMA 1998; 279: 756-61.
14. Mofenson L, Korelitz J, Meyer WA, Bethel J, Rich K, Pahwa S et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long term mortality risk in HIV-1 infected children. J Infect Dis 1997; 175, 1029-38.
15. Ziegler JB, Cooper DA, Gold J, Johnston R. Postnatal transmission of AIDS-associated retrovirus. Lancet 1985; 1: 896-8.
16. Pediatric AIDS Clinical Trials Group Protocol, 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80.
17. The International Perinatal HIV Group. The Mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. N Engl J Med 1999; 340: 977-87.
18. Centers for Disease Control. 1994 Revised human immunodeficiency virus pediatric classification system: clinical categories. MMWR Morbid Mortal Wkly Rep 1994; 43: 1-10.
19. Nøkleby H, red. Veiledning om vaksinasjon. Oslo: Statens institutt for folkehelse, 1998: 30.
20. Sharland M, Gibb D, Tudor-Williams G, Walters S, Novelli V. Paediatric HIV infection. Arch Dis Child 1997; 76: 293-7.
21. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992; 339: 1007-12.
22. Smith D. Compliance and toxicity concerns with antiretroviral therapy. J HIV Therapy 1998; 3: 55-7.